Thermo Fisher Scientific (TMO) has recently displayed mixed performance in markets. While often outperforming the broader markets, TMO has seen periods of dip and underperformance too. The company faces a probe regarding its deal with Olink by the UK's Competition and Markets Authority (CMA). However, the insider selling of TMO stocks raises concerns about potential bearish signals. The company's leadership in the AI and robotics sectors is notable. Its performance in the Q1 2024 reports exceeded expectations, offering an adjusted EPS which outperformed analysts' expectations, hitting $5.11 EPS and $10.34 billion in revenue. First quarter 2024 results have also sparked new analysts' forecasts following its promising performance in 2023, despite economic challenges. Investors remain confident in TMO's stock which has enjoyed a robust financial performance and stock growth of 40% in last five months. TMO recently increased its quarterly dividend and made an aggressive move by authorizing $4 billion of share repurchases. Still, the company has reduced its outlook for the second-straight quarter due to a weakening market.
Thermo Fisher Scientific TMO News Analytics from Tue, 12 Sep 2023 07:00:00 GMT to Fri, 10 May 2024 11:20:00 GMT - Rating 2 - Innovation 6 - Information 8 - Rumor 5
